Pfizer and Acura Pharmaceuticals announced that the FDA has approved Oxecta (oxycodone HCl tablets) for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate. Oxecta is an immediate-release formulation of oxycodone that utilizes Acura’s Aversion technology, a proprietary composition of common pharmaceutical ingredients, to discourage common methods of tampering associated with opioid abuse and misuse.

Oxecta is a Schedule C-II controlled substance.

For more information call (800) 776-3637 or visit